Rhythm Pharmaceuticals Inc RYTM:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD

After Hours: Last | 04/26/24 EDT

38.28UNCH (UNCH)

Volume

12,463

38.28

+0.13 (+0.34%)

Volume

292,581

52 week range

15.50 - 52.57

Open38.39
Day High38.89
Day Low37.36
Prev Close38.15
52 Week High52.57
52 Week High Date02/12/24
52 Week Low15.50
52 Week Low Date07/06/23

Key Stats

Market Cap2.334B
Shares Out60.96M
10 Day Average Volume0.52M
Dividend-
Dividend Yield-
Beta1.95
YTD % Change-16.73

KEY STATS

Open38.39
Day High38.89
Day Low37.36
Prev Close38.15
52 Week High52.57
52 Week High Date02/12/24
52 Week Low15.50
52 Week Low Date07/06/23
Market Cap2.334B
Shares Out60.96M
10 Day Average Volume0.52M
Dividend-
Dividend Yield-
Beta1.95
YTD % Change-16.73

RATIOS/PROFITABILITY

EPS (TTM)-3.21
P/E (TTM)-11.94
Fwd P/E (NTM)-9.11
EBITDA (TTM)-182.599M
ROE (TTM)-85.10%
Revenue (TTM)77.428M
Gross Margin (TTM)87.99%
Net Margin (TTM)-238.52%
Debt To Equity (MRQ)62.53%

EVENTS

Earnings Date05/07/2024
Ex Div Date-
Div Amount-
Split Date-
Split Factor-

Latest On Rhythm Pharmaceuticals Inc

Lightning Round: It's a great time to sell Aspin Aerogels, says Jim CramerApril 18, 2024CNBC.com
Cramer's Lighting Round: Sell Aspen AerogelsApril 18, 2024CNBC.com
Biotech stocks are ready to break out. They just need one more thingApril 10, 2024CNBC.com

Content From Our Affiliates

Analysts Conflicted on These Healthcare Names: Gilead Sciences (GILD), Rhythm Pharmaceuticals (RYTM) and Dexcom (DXCM)April 26, 2024TipRanks
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024April 24, 2024TipRanks
Rhythm Pharmaceuticals Announces New Employment Inducement GrantsApril 16, 2024TipRanks
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Amylyx Pharmaceuticals Inc (AMLX) and Rhythm Pharmaceuticals (RYTM)April 16, 2024TipRanks
Buy Rating Justified by Rhythm Pharmaceuticals’ Strong Market Entry and Promising PipelineApril 10, 2024TipRanks

Profile

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or...

David Meeker M.D.

Chairman of the Board, President, Chief Executive Officer

Hunter Smith

Chief Financial Officer, Treasurer

Yann Mazabraud

Executive Vice President, Head of International

Jennifer Chien

Executive Vice President, Head of North America

Address

222 Berkeley Street, 12th Floor Boston

Boston, MA

02116

United States

http://www.rhythmtx.com

Top Peers

SYMBOL	LAST	CHG	%CHG
ARVN Arvinas Inc	32.37	+0.77	+2.44%
MRUS Merus NV	45.04	+0.11	+0.24%
KYMR Kymera Therapeutics Inc	33.37	+0.02	+0.06%
NTLA Intellia Therapeutics Inc	20.76	+0.74	+3.70%
RNA Avidity Biosciences Inc	24.36	+0.53	+2.22%